RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:99938

Autosomal dominant Charcot-Marie-Tooth disease type 2D

medium confidenceDisorder

Also known as: CMT2D

Publications

378

79.7th percentile

Trials

1

Interventional, condition-specific

Researchers

1,036

Distinct authors in sample

Gene link

GARS1

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor , characterized by distal weakness primarily and predominantly occurring in the upper limbs and tendon reflexes absent or reduced in the arms and decreased in the legs. Progression is slow.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

Charcot-Marie-Tooth disease type 2 caused by mutation in GARS · Charcot-Marie-Tooth disease, type 2D · GARS Charcot-Marie-Tooth disease type 2 · autosomal dominant Charcot-Marie-Tooth disease type 2D

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — GARS1

  2. LiteraturePresent

    378 matched papers (214 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    1 matched on ClinicalTrials.gov (1 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (GARS1).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

378

378 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

378 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

214 in the last 10 years · medium confidence · 79.7th percentile (publications denominator)

Phrase hits: 378 · MeSH hits: 1

Open Europe PMC search

Who's working on it?

1,036

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Sleigh JN28 papers · 2026

    Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.

    Papers in Europe PMC
  2. 02
    Burgess RW27 papers · 2026

    The Jackson Laboratory, Bar Harbor, ME 04609, USA.

    Papers in Europe PMC
  3. 03
    Yang XL16 papers · 2024

    Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

    Papers in Europe PMC
  4. 04
    Schiavo G14 papers · 2025

    Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, UK.

    Papers in Europe PMC
  5. 05
    Antonellis A13 papers · 2024

    Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

    Papers in Europe PMC
  6. 06
    Wei N9 papers · 2022

    Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

    Papers in Europe PMC
  7. 07
    Bai G8 papers · 2023

    Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

    Papers in Europe PMC
  8. 08
    Rhymes ER8 papers · 2026

    Department of Neuromuscular Diseases and UCL Queen Square Motor Neuron Disease Centre, Queen Square Institute of Neurology, University College London, London, UK.

    Papers in Europe PMC
  9. 09
    Jordanova A7 papers · 2017

    Molecular Neurogenomics Group, Department of Molecular Genetics, VIB, University of Antwerp, Antwerp 2610, Belgium; Neurogenetics Laboratory, Institute Born-Bunge, University of Antwerp, Antwerp 2610, Belgium. Electronic address: albena.jordanova@molgen.vib-ua.be.

    Papers in Europe PMC
  10. 10
    Spaulding EL7 papers · 2022

    The Jackson Laboratory, Bar Harbor, ME 04609, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

1

interventional trials for this specific condition

1 interventional trial matched this specific condition name; 1 currently recruiting in our sample. 41 trials are registered for Charcot-Marie-Tooth disease, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).

medium confidence · 76.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

1 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: Charcot-Marie-Tooth disease

41

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Autosomal dominant Charcot-Marie-Tooth disease type 2D" OR "CMT2D" OR "Charcot-Marie-Tooth disease type 2 caused by mutation in GARS" OR "Charcot-Marie-Tooth disease, type 2D" OR "GARS Charcot-Marie-Tooth disease type 2"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Charcot-Marie-Tooth disease, Type 2D

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal dominant Charcot-Marie-Tooth disease type 2D" OR "CMT2D" OR "Charcot-Marie-Tooth disease type 2 caused by mutation in GARS" OR "Charcot-Marie-Tooth disease, type 2D" OR "GARS Charcot-Marie-Tooth disease type 2" OR "GARS1"

Recall-expansion terms: GARS1

Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"Charcot-Marie-Tooth disease"

Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (378) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T06:43:09.093Z